Ocrevus ™ (ocrelizumab) listed on the Pharmaceutical Benefits Scheme (PBS)

01 February 2018

Ocrevus ™ is used in relapsing remitting multiple sclerosis (RRMS) and this morning, the Federal Government announced the listing of the drug on the PBS.

Ocrevus ™ decreases the number of flare-ups, and slows the worsening of RRMS. This results in a significant improvement in quality of life for sufferers, and following today’s government announcement, those eligible for Ocrevus ™ for RRMS, will pay a maximum of $39.50 per script, or $6.40 for concessional patients.

If you have questions about Ocrevus ™, please ring our MSWA MS nurses on 9365 4888.

Read more: MS Australia